​

Ovid Therapeutics (OVID) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OVID Stock Forecast

Ovid Therapeutics (OVID) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $2.50, with a high of $3.00 and a low of $2.00. This represents a 51.52% increase from the last price of $1.65.

High: $3 Avg: $2.5 Low: $2 Last Closed Price: $1.65

OVID Stock Rating

Ovid Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

OVID Price Target Upside V Benchmarks

TypeNameUpside
StockOvid Therapeutics51.52%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts222
Avg Price Target$2.50$2.50$2.50
Last Closing Price$1.65$1.65$1.65
Upside/Downside51.52%51.52%51.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-9---9
Nov, 2517---8
Oct, 2516---7
Sep, 2516---7
Aug, 2515---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 11, 2025Boobalan PachaiyappanRoth Capital$3.00$1.6384.05%81.82%
Nov 24, 2025H.C. Wainwright$2.00$1.4042.86%21.21%
Jul 02, 2024Raghuram SelvarajuH.C. Wainwright$3.00$0.86248.84%81.82%
May 20, 2024Thomas ShraderBTIG$11.00$3.14250.32%566.67%
May 14, 2024Francois BriseboisOppenheimer$8.00$3.23147.68%384.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2025Roth CapitalBuyinitialise
Nov 24, 2025H.C. WainwrightBuyBuyhold
Oct 10, 2025B. RileyBuyBuyhold
Aug 08, 2025B. RileyBuyBuyhold
Mar 24, 2025BTIGBuyBuyhold
Mar 12, 2025WedbushOutperformOutperformhold
Jan 29, 2025OppenheimerPerformOutperformupgrade
Aug 19, 2024CitigroupUnderperformUnderperformhold
Jul 26, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-18 $-11 $-4 $3 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.38$1.78$-0.73$-0.74$-21.15----
Avg Forecast$-1.35$2.02$-0.75$-0.21$-0.47$-0.61$-0.34$-0.80$-0.80
High Forecast$0.24$6.56$0.14$0.14$-0.45$-0.15$0.47$-0.70$0.20
Low Forecast$-4.39$-0.36$-2.52$-0.57$-0.48$-0.78$-0.78$-0.98$-2.77
Surprise %2.22%-11.88%-2.67%252.38%4400.00%----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.62M$208.38M$1.50M$391.69K$566.00K----
Avg Forecast$11.08M$208.39M$1.47M$8.79M$662.78K$4.62M$26.61M$4.03M$21.59M
High Forecast$30.26M$569.19M$4.12M$9.54M$760.56K$13.29M$76.61M$11.59M$62.16M
Low Forecast$1.04M$19.61M$124.51K$8.28M$532.39K$174.91K$1.01M$152.46K$817.87K
Surprise %13.89%-0.00%2.42%-95.54%-14.60%----

Net Income Forecast

$-350M $-180M $-10M $160M $330M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-80.73M$122.83M$-51.41M$-52.34M$-26.43M----
Avg Forecast$-95.23M$142.45M$-53.11M$-14.94M$-32.50M$-42.71M$-28.91M$-59.29M$-56.70M
High Forecast$16.92M$463.05M$10.07M$10.19M$-32.00M$-10.69M$32.91M$-49.41M$14.22M
Low Forecast$-309.56M$-25.31M$-177.97M$-40.06M$-33.64M$-54.98M$-55.10M$-69.17M$-195.18M
Surprise %-15.22%-13.77%-3.20%250.44%-18.67%----

OVID Forecast FAQ

Is Ovid Therapeutics stock a buy?

Ovid Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ovid Therapeutics is a favorable investment for most analysts.

What is Ovid Therapeutics's price target?

Ovid Therapeutics's price target, set by 14 Wall Street analysts, averages $2.5 over the next 12 months. The price target range spans from $2 at the low end to $3 at the high end, suggesting a potential 51.52% change from the previous closing price of $1.65.

How does Ovid Therapeutics stock forecast compare to its benchmarks?

Ovid Therapeutics's stock forecast shows a 51.52% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ovid Therapeutics over the past three months?

  • December 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ovid Therapeutics’s EPS forecast?

Ovid Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.61, marking a -97.12% decrease from the reported $-21.15 in 2024. Estimates for the following years are $-0.34 in 2026, $-0.8 in 2027, and $-0.8 in 2028.

What is Ovid Therapeutics’s revenue forecast?

Ovid Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.62M, reflecting a 715.81% increase from the reported $566K in 2024. The forecast for 2026 is $26.61M, followed by $4.02M for 2027, and $21.59M for 2028.

What is Ovid Therapeutics’s net income forecast?

Ovid Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-42.705M, representing an 61.56% increase from the reported $-26.433M in 2024. Projections indicate $-28.905M in 2026, $-59.288M in 2027, and $-56.7M in 2028.